Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Therapeutic Use
- 11 Apr 2019 Status changed from suspended to recruiting.
- 05 Mar 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 05 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2020.